title: Long-term intake of sesamin improves left ventricular remodelling in spontaneously hypertensive rats.
abstract: This study was designed to evaluate the in vivo cardioprotective effects of food-derived sesamin in spontaneously hypertensive rats (SHR). The study was performed with 17-week-old male normotensive Wistar-Kyoto rats (WKY) and SHR which are untreated or treated with orally administered sesamin for 16 weeks before they were sacrificed. Long-term treatment with sesamin obviously improved left ventricular (LV) hypertrophy and fibrosis in SHR, as indicated by the decrease of LV weight/body weight, myocardial cell size, cardiac fibrosis and collagen type I expression as well as the amelioration of the LV ultrastructure. These effects were associated with reduced systolic blood pressure, enhanced cardiac total antioxidant capability and decreased malondialdehyde content, nitrotyrosine level and transforming growth factor β1 (TGF-β1) expression. All these results suggest that chronic treatment with sesamin improves LV remodeling in SHR through alleviation of oxidative and nitrative stress, reduction of blood pressure and downregulation of TGF-β1 expression.
authors.affiliation: Department of Pharmacology, Third-Grade Pharmacology Laboratory of State Administration of Traditional Chinese Medicine, Wannan Medical College, Wuhu, Anhui 241002, China.
authors.forename: Wen-xing
authors.initials: WX
authors.lastname: Li
authors.forename: Xiang
authors.initials: X
authors.lastname: Kong
authors.forename: Jun-xiu
authors.initials: JX
authors.lastname: Zhang
authors.forename: Jie-ren
authors.initials: JR
authors.lastname: Yang
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D024042:Collagen Type I / Q000235:genetics / Q000378:metabolism; D004149:Dioxoles / Q000494:pharmacology*; D004195:Disease Models, Animal; D015536:Down-Regulation; D005355:Fibrosis / Q000188:drug therapy / Q000473:pathology; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006973:Hypertension / Q000188:drug therapy / Q000473:pathology; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000473:pathology; D017705:Lignans / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000378:metabolism; D014443:Tyrosine / Q000031:analogs & derivatives / Q000097:blood; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; D024042:Collagen Type I; D004149:Dioxoles; D017705:Lignans; D012333:RNA, Messenger; D053773:Transforming Growth Factor beta1; C002744:3-nitrotyrosine; D014443:Tyrosine; D008315:Malondialdehyde; C054125:sesamin